SUSPUP

SUSPUP = [Natrium]_Serum / [Natrium]_Urin / ([Kalium]_Serum / [Kalium]_Urin)

SUSPPUP = [Natrium]_Serum / [Natrium]_Urin / (([Kalium]_Serum)² / [Kalium]_Urin)

Beide Quotienten eignen sich als Screening-Parameter für die funktionelle Evaluation des Renin-Angiotensin-II-Aldosteron-Systems. Als Bestätigungstest kommt der Aldosteron-Renin-Quotient zum Einsatz.

1. Willenberg HS, Kolentini C, Quinkler M, Cupisti K, Krausch M, Schott M, Scherbaum WA. The serum sodium to urinary sodium to (serum potassium)² to urinary potassium (SUSPPUP) ratio in patients with primary aldosteronism. Eur J Clin Invest. 2009 Jan;39(1):43-50. doi: 10.1111/j. 365-2362.2008.02060.x. Epub 2008 Dec 1. PMID 19067735.
2. Yin GS, Zhang SL, Yan L, Li F, Qi YQ, Chen ZC, Cheng H. [New index of using serum sodium and potassium and urine sodium and potassium jointly in screening primary aldosteronism in hypertensive patients]. Zhonghua Yi Xue Za Zhi. 2010 Apr 13;90(14):962-6. PMID 20646645.
3. Balaş M, Zosin I, Maser-Gluth C, Hermsen D, Cupisti K, Schott M, Schinner S, Knoefel WT, Scherbaum WA, Willenberg HS. Indicators of mineralocorticoid excess in the evaluation of primary aldosteronism. Hypertens Res. 2010 Aug;33(8):850-6. doi: 10.1038/hr.2010.76. Epub 2010 Jun 3. PMID 20520614.
4. Steichen O, Blanchard A, Plouin PF. Assessment of serum sodium to urinary sodium divided by (serum potassium)² to urinary potassium as a screening tool for primary aldosteronism. Eur J Clin Invest. 2011 Feb;41(2):189-94. doi: 10.1111/j.1365-2362.2010.02401.x. Epub 2010 Oct 18. PMID 20955208.